DYN (Dyne Therapeutics) Quick Ratio : 15.60 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Dyne Therapeutics's quick ratio for the quarter that ended in Dec. 2024 was 15.60.

Dyne Therapeutics has a quick ratio of 15.60. It generally indicates good short-term financial strength.

The historical rank and industry rank for Dyne Therapeutics's Quick Ratio or its related term are showing as below:

DYN' s Quick Ratio Range Over the Past 10 Years
Min: 2.53 Med: 11.47 Max: 31.83
Current: 15.6

During the past 7 years, Dyne Therapeutics's highest Quick Ratio was 31.83. The lowest was 2.53. And the median was 11.47.

DYN's Quick Ratio is ranked better than
89.6% of 1500 companies
in the Biotechnology industry
Industry Median: 3.38 vs DYN: 15.60

Dyne Therapeutics Quick Ratio Historical Data

The historical data trend for Dyne Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyne Therapeutics Quick Ratio Chart

Dyne Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Quick Ratio

Get a 7-Day Free Trial

31.83

13.31

9.46

2.53

15.60

Dyne Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Quick Ratio	Get a 7-Day Free Trial															2.53	21.83	26.63	17.02	15.60

Competitive Comparison of Dyne Therapeutics's Quick Ratio

For the Biotechnology subindustry, Dyne Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyne Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's Quick Ratio falls into.

Save Embed

;

Save Embed

;

Dyne Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Dyne Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(659.279	-	0)	/	42.258
	=	15.60

Dyne Therapeutics's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(659.279	-	0)	/	42.258
	=	15.60

Dyne Therapeutics (NAS:DYN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Dyne Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyne Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Trapelo Road, Waltham, MA, USA, 02451

Website

https://www.dyne-tx.com

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Executives

Richard William Scalzo	officer: See Remarks	25 ALBERTA LANE, HOLLISTON MA 01746
Oxana Beskrovnaya	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Dirk Kersten	director, 10 percent owner	C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Carlo Incerti	director	FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Jason P Rhodes	director, 10 percent owner	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Susanna Gatti High	officer: Chief Operating Officer	75 LORIMER ROAD, BELMONT MA 02141
Wildon Farwell	officer: Chief Medical Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Jonathan Mcneill	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Joshua T Brumm	director, officer: See Remarks	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Romesh Subramanian	10 percent owner, officer: Chief Scientific Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451